Key facts
- SiteOne Therapeutics’s last known valuation is $1.0B (Jul 2025).
- It has raised $117.7M; the latest was Merger/Acquisition ($1.0B) in Jul 2025.
- Status: Acquired/Merged.
- ·Watchlist + deal alerts for SiteOne Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for SiteOne Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SiteOne Therapeutics
Developer of novel pain therapeutics designed to offer treatment for acute and chronic pain. The company's drugs provide treatment for neuropathic pain through novel pain therapeutics without the limitations of existing drugs, such as opioids, enabling healthcare professionals to deliver an optimal treatment to their patients and improve efficiency.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2010
- Employees
- 22
- Website
- siteonetherapeutics.com/
- Ownership
- Acquired/Merged
SiteOne Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SiteOne Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SiteOne Therapeutics in its N-PORT filings yet. We sweep new filings monthly.